


PATENT  
ATTORNEY DOCKET NO. 50026/058001

Certificate of Mailing	
Date of Deposit: <u>March 14, 2007</u>	Label Number: <u>EV 919881244 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Elvis De La Cruz</u> Printed name of person mailing correspondence	 Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Okano et al. Confirmation No.: 5137  
Serial No.: 10/578,085 Art Unit: Not yet assigned  
Filed: May 3, 2006 Examiner: Not yet assigned  
Customer No.: 21559  
Title: METHOD FOR PRODUCING GENE TRANSFERRED DENDRITIC CELLS

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. Also enclosed is a copy of a search report from a corresponding European application.

WO 97/16539, WO 00/70055, WO 00/70070, WO 03/025570, WO 03/029475, and WO 2004/038029, and Japanese Patent Application Nos. JP 2000-253876 and JP


2002-272465 are written in the Japanese language. English language translations of these documents are enclosed.

Kunisawa et al., "Application of Novel Drug Delivery System, Fusogenic Liposome, for Cancer Therapy," *Jpn. J. Cancer Chemother (Gan To Kagaku Ryoho)* 28(5):577-583 (2001) is written in the Japanese language. An English language "Summary" appears on pages 577-578 of this reference.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Date: March 14, 2007

Respectfully submitted,  
  
James D. DeCamp, Ph.D.  
Reg. No. 43,580

  
Jeffrey P. Kessler  
Reg. No. 57,727 for

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50026/058001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/578,085
		Applicant Okano et al.
		Filing Date May 3, 2006
		Group Not yet assigned
		IDS Filed March 14, 2007
		Customer No. 21559
(37 C.F.R. § 1.98(b))		

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,645,760	Nov. 11, 2003	Nagai et al.			
	6,723,532	Apr. 20, 2004	Nagai et al.			
	2002/0002143	Jan. 3, 2002	Kano et al.			
	2002/0169306	Nov. 14, 2002	Kitazato et al.			
	2003/0022376	Jan. 30, 2003	Kitazato et al.			
	2003/0166252	Sep. 4, 2003	Kitazato et al.			
	2003/0170266	Sep. 11, 2003	Kitazato et al.			
	2005/0266566	Dec. 1, 2005	Nagai et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 0 864 645	Sep. 16, 1998	EPO			
	EP 1 186 667	Mar. 13, 2002	EPO			
	JP 2000-253876	Sep. 19, 2000	Japan			Yes
	JP 2002-272465	Sep. 24, 2002	Japan			Yes
	WO 97/16539	May 9, 1997	WIPO			Yes
	WO 00/70055	Nov. 23, 2000	WIPO			Yes
	WO 00/70070	Nov. 23, 2000	WIPO			Yes
	WO 03/025570	Mar. 27, 2003	WIPO			Yes
	WO 03/029475	Apr. 10, 2003	WIPO			Yes
	WO 2004/038029	May 6, 2004	WIPO			Yes

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50026/058001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/578,085
(37 C.F.R. § 1.98(b))		Applicant Okano et al.
		Filing Date May 3, 2006
		Group Not yet assigned
		IDS Filed March 14, 2007
		Customer No. 21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Akiyama et al., "Enhancement of Antitumor Immunity Against B16 Melanoma Tumor Using Genetically Modified Dendritic Cells to Produce Cytokines," <i>Gene Ther.</i> 7(24):2113-2121 (2000).
	Alemany et al., "Replicative Adenoviruses for Cancer Therapy," <i>Nat. Biotechnol.</i> 18(7):723-727 (2000).
	Banchereau et al., "Dendritic Cells and the Control of Immunity," <i>Nature</i> 392(6673):245-252 (1998).
	Camporeale et al., "Critical Impact of the Kinetics of Dendritic Cells Activation on the in Vivo Induction of Tumor-specific T Lymphocytes," <i>Cancer Res.</i> 63(13):3688-3694 (2003).
	Cremer et al., "Inhibition of Human Immunodeficiency Virus Transmission to CD4 <sup>+</sup> T Cells after Gene Transfer of Constitutively Expressed Interferon $\beta$ to Dendritic Cells," <i>Hum. Gene Ther.</i> 11(12):1695-1703 (2000).
	Curiel, "The Development of Conditionally Replicative Adenoviruses for Cancer Therapy," <i>Clin. Cancer Res.</i> 6(9):3395-3399 (2000).
	Goldszman et al., "Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-lived Protective CD4 <sup>+</sup> and CD8 <sup>+</sup> T Cell Immunity Against B16 Melanoma," <i>J. Immunol.</i> 171(11):5940-5947 (2003).
	He et al., "Inhibition of Tumor Growth with a Vaccine Based on Xenogeneic Homologous Fibroblast Growth Factor Receptor-1 in Mice," <i>J. Biol. Chem.</i> 278(24):21831-21836 (2003).
	Hiraoka et al., "Enhanced Tumor-Specific Long-Term Immunity of Hemagglutinating Virus of Japan-mediated Dendritic Cell-tumor Fused Cell Vaccination by Coadministration with CpG Oligodeoxynucleotides," <i>J. Immunol.</i> 173(7):4297-4307 (2004).
	Hsu et al., "Vaccination of Patients with B-cell Lymphoma Using Autologous Antigen-pulsed Dendritic Cells," <i>Nat. Med.</i> 2(1):52-58 (1996).
	Imboden et al., "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <i>Cancer Res.</i> 61(4):1500-1507 (2001).
	Jin et al., "Recombinant Sendai Virus Provides a Highly Efficient Gene Transfer into Human Cord Blood-derived Hematopoietic Stem Cells," <i>Gene Ther.</i> 10(3):272-277 (2003).
	Jonuleit et al., "Efficient Transduction of Mature CD83 <sup>+</sup> Dendritic Cells Using Recombinant Adenovirus Suppressed T Cell Stimulatory Capacity," <i>Gene Ther.</i> 7(3):249-254 (2000).
	Kaneda, "Development of HVJ Envelope Vector for Cancer Therapy," <i>Seikagaku</i> 75(8):737(#3S51-6) (2003).
	Kanyama et al., "Usefulness of Repeated Direct Intratumoral Gene Transfer Using Hemagglutinating Virus of Japan-liposome Method for Cytosine Deaminase Suicide Gene Therapy," <i>Cancer Res.</i> 61(1):14-18 (2001).
	Kirn, "Virotherapy for Cancer: Current Status, Hurdles, and Future Directions," <i>Cancer Gene Ther.</i> 9(12):959-960 (2002).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50026/058001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/578,085
		Applicant Okano et al.
		Filing Date May 3, 2006
		Group Not yet assigned
		IDS Filed March 14, 2007
		Customer No. 21559
(37 C.F.R. § 1.98(b))		

	Kunisawa et al., "Application of Novel Drug Delivery System, Fusogenic Liposome, for Cancer Therapy," <i>Jpn. J. Cancer Chemother (Gan To Kagaku Ryoho)</i> 28(5):577-583 (2001).
	Le Bon et al., "Cross-priming of CD8 <sup>+</sup> T Cells Stimulated by Virus-induced Type I Interferon," <i>Nat. Immunol.</i> 4(10):1009-1015 (2003).
	Lundqvist et al., "Nonviral and Viral Gene Transfer into Different Subsets of Human Dendritic Cells Yield Comparable Efficiency of Transfection," <i>J. Immunother.</i> 25(6):445-454 (2002).
	Min et al., "Dendritic Cells Genetically Engineered to Express Fas Ligand Induce Donor-specific Hyporesponsiveness and Prolong Allograft Survival," <i>J. Immunol.</i> 164(1):161-167 (2000).
	Mineta et al., "Attenuated Multi-mutated Herpes Simplex Virus-1 for the Treatment of Malignant Gliomas," <i>Nat. Med.</i> 1(9):938-943 (1995).
	Mullins et al., "Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control," <i>J. Exp. Med.</i> 198(7):1023-1034 (2003).
	Nakahara et al., "Dendritic Cells Stimulated with a Bacterial Product, OK-432, Efficiently Induce Cytotoxic T Lymphocytes Specific to Tumor Rejection Peptide," <i>Cancer Res.</i> 63(14):4112-4118 (2003).
	Nestle et al., "Vaccination of Melanoma Patients with Peptide- or Tumor Lysate-pulsed Dendritic Cells," <i>Nat. Med.</i> 4(3):328-332 (1998).
	Okada et al., "Dendritic Cells Transduced with gp100 Gene by RGD Fiber-mutant Adenovirus Vectors Are Highly Efficacious in Generating Anti-B16BL6 Melanoma Immunity in Mice," <i>Gene Ther.</i> 10(22):1891-1902 (2003).
	Okano et al., "Recombinant Sendai Virus Vectors for Activated T Lymphocytes," <i>Gene Ther.</i> 10(16):1381-1391 (2003).
	Sasaki et al., "Efficient and Stable Sendai Virus-mediated Gene Transfer into Primate Embryonic Stem Cells with Pluripotency Preserved," <i>Gene Ther.</i> 12(3):203-210 (2005). [online publication October 14, 2004]
	Shibata et al., "Induction of Efficient Antitumor Immunity against Established B16 Melanoma Using Highly Activated Dendritic Cells Produced by Recombinant Sendai Virus Vector" <i>The 10<sup>th</sup> Annual Meeting 2004: The Japan Society of Gene Therapy Poster Session</i> 2:088 (2004).
	Steinman, "The Dendritic Cell System and Its Role in Immunogenicity," <i>Annu. Rev. Immunol.</i> 9:271-296 (1991).
	Steinman, "Dendritic Cells and Immune-Based Therapies," <i>Exp Hematol.</i> 24(8):859-862 (1996).
	Steitz et al., "Depletion of CD25 <sup>+</sup> CD4 <sup>+</sup> T Cells and Treatment with Tyrosinase-Related Protein 2-Transduced Dendritic Cells Enhance the Interferon $\alpha$ -induced, CD8 <sup>+</sup> T-Cell-Dependent Immune Defense of B16 Melanoma," <i>Cancer Res.</i> 61(24):8643-8646 (2001).
	Strome et al., "Strategies for Antigen Loading of Dendritic Cells to Enhance the Antitumor Immune Response," <i>Cancer Res.</i> 62(6):1884-1889 (2002).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50026/058001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/578,085
		Applicant Okano et al.
		Filing Date May 3, 2006
		Group Not yet assigned
		IDS Filed March 14, 2007
		Customer No. 21559

	Sumimoto et al., "Rapid and Efficient Generation of Lentivirally Gene-modified Dendritic Cells from DC Progenitors with Bone Marrow Stromal Cells," <i>J. Immunol. Methods</i> 271(1-2):153-165 (2002).
	Teitz-Tennenbaum et al., "Radiotherapy Potentiates the Therapeutic Efficacy of Intratumoral Dendritic Cell Administration," <i>Cancer Res.</i> 63(23):8466-8475 (2003).
	Xia et al., "Lymphotoxin Cotransfection Enhances the Therapeutic Efficacy of Dendritic Cells Genetically Modified with Melanoma Antigen gp100," <i>Gene Ther.</i> 9(9):592-601 (2002).
	Search Report from European Application No. 04793197.7, mailed December 6, 2006.
	English Translation of International Preliminary Examination Report for PCT/JP2004/016089.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	